Incannex reports fiscal Q3 2025 results and clinical progress
Net loss narrows to $3.97 million from $6.03 million; IHL-42X Phase 2 dosing is complete with topline data expected July 2025.
Latest Incannex Healthcare News & Updates
See the latest news and media coverage for Incannex. We track all announcements, press releases, and industry mentions in real time, all in one place.
Clinical-stage pharmaceutical company developing combination medicines
incannex.com- Headquarters
- Melbourne, Australia
- Founded year
- 2015
- Company type
- Public company
- Number of employees
- 17–50
- Industry
- Pharmaceuticals
Last updated
Latest news about Incannex Healthcare (Incannex)
In short: Incannex completed RePOSA, dosed DReAMzz’s first patient and received FDA Fast Track designation for IHL-42X.
Company announcements
Incannex reports fiscal Q2 2025 results and business updates
Net loss was $6.3 million versus $4.3 million a year earlier, with cash of $2.1 million and positive IHL-42X pharmacokinetic results.
Incannex reports fiscal first quarter 2025 financial results
Net loss widens to $5.4 million from $0.7 million, cash falls to $3.6 million, and it appoints Lou Barbato as chief medical officer.
Incannex narrows fiscal 2024 net loss to $18.5 million
The company also reports positive Phase 2 results for PSX-001 and begins dosing in the IHL-42X Phase 2/3 trial.
Media coverage
What's Going On With Incannex Stock?
Incannex Healthcare Inc. (NASDAQ:IXHL) shares are trading higher Wednesday after the company announced its Psi-GAD1 trial met its primary endpoint. Incannex said that its Phase...
Incannex gets green light from US FDA for Phase 2/3 Pivotal Clinical Trialfor obstructive sleep apnoea
The US Food and Drug Administration (FDA) has approved Incannex Healthcare's Investigational New Drug (IND) application for IHL-42X, which treats obstructive sleep apnoea (OSA), a...
Incannex Announces Intention to Redomicile to United States, List all Shares on Nasdaq
Incannex to redomicile to the United States via a Scheme of Arrangement pursuant to Australian law A newly formed Delaware corporation (Incannex Healthcare Inc.) will...
Incannex Reveals Clinical Trial Results On Dronabinol-Based Drug For Obstructive Sleep Apnea
Incannex Healthcare Limited IXHL IHL, a clinical-stage pharmaceutical company developing medicinal cannabinoid pharmaceutical products and psychedelic medicine therapies for unmet medical needs, has completed an...
Never miss news about Incannex
Track Incannex and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.
Incannex competitors & trending companies
Browse news for competitors to Incannex and other trending companies.
Sensorium
Definium Therapeutics
Gabather
Helus
Compass
GH Research
AtaiBeckley
RG
Curis
MPLX
Mosaic
Fortitude Re
Brit
Convex
Sompo
Somers Group
Pelagos
Vantage
Premia
Mereo
Longtail Re
Assured Guaranty
BMA
NAIC
IAIS
Ascot
GFIA
SiriusPoint
Lancashire
AXIS
White Mountains
PartnerRe
Antares
Lockton Finland
RenaissanceRe
MS Re